Trial Profile
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 30 Nov 2021
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 17 Nov 2021 Status changed from recruiting to completed.
- 26 Apr 2017 New trial record